SCHEMBL5160914

SCHEMBL5160914

CCN(CC)C(=O)CC(=O)c1ccsc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
HDAC1 Q13547 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
DAO P14920 1/20 0.44
KIF11 P52732 1/20 0.43
HSD11B1 P28845 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.40
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
HPGD P15428 1/20 0.39
DPP4 P27487 2/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TDP1 Q9NUW8 1/20 0.36
MLYCD O95822 1/20 0.36
ABCC1 P33527 1/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5158655 0.83 CES2 (0.48) CES2CES1HDAC1LCKFYN
SCHEMBL22721318 0.80 CES1 (0.62) CES2CES1HDAC1LCKFYN
SCHEMBL2011772 0.79 LCK (0.55) CES2CES1HDAC1LCKFYN
SCHEMBL3041357 0.77 CES2 (0.54) CES2CES1HDAC1LCKFYN
SCHEMBL4055310 0.77 KDM4E (0.53) CES2CES1HDAC1LCKFYN
SCHEMBL4876161 0.76
SCHEMBL10607038 0.75 HPGD (0.59) CES1HDAC1HPGDNPC1RAB9A
SCHEMBL5160555 0.75 CES2 (0.47) CES2CES1HDAC1LCKFYN
SCHEMBL4336119 0.74 LCK (0.59) CES2CES1HDAC1LCKFYN
SCHEMBL1694609 0.74 ALDH1A1 (0.50) CES2CES1HDAC1LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO CES2 441/4885CES1 382/4885HDAC1 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.